Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells

Scandinavian Journal of Immunology

Volumn 59, Issue 5, 2004, Pages 432-439

  Ogawa, F ^a   Iinuma, H ^a   Okinaga, K ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CANCER VACCINE; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HYBRID PROTEIN; INTERLEUKIN 2; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG POTENCY; GENETIC TRANSDUCTION; INTERFERON PRODUCTION; INTERMETHOD COMPARISON; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FIBROSARCOMA; FLOW CYTOMETRY; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MICE; NEOPLASM METASTASIS; SPLEEN; TRANSDUCTION, GENETIC;

EID: 2642557198     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01411.x     Document Type: Article

References (29)

1. Stainman RM, Van Voorhis WC, Spalding DM. Dendritic cells. In: Weir DM, Herzenberg LA, Blackwell C eds. Handbook of Experimental Immunology, London: Blackwell Scientific Publications 1986, pp. 49.1-49.9.
2. Rissoan MC, Soumelis V, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-6.
3. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
4. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
5. Imuro MA, Manici S, Russo V et al. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen. Cancer Res 1999;59:2287-91.
6. Nestle FO, Aliagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
7. Gong J, Chen D, Kashiwaba M et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
8. Hart I, Colaco C. Fusion induces tumour rejection. Nature 1997;388:626-7.
9. Guo Y, Mengchao W, Chen H et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263:518-20.
10. Wang J, Saffold S, Cao X et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998;161:5516-24.
11. Kikuchi T, Akasaki Y, Irie M et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001;50:337-44.
12. Kugler A, Stuhler G, Walden S et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
13. Rosenberg SA, Lotze MT. Cancer immunotherapy interleukin-2 and interleukin-2-activated lymphocytes. Ann Rev Immunol 1986;4:681-709.
14. + T-cell immunity and NK activity. Cancer Gene Ther 2001;8:321-32.
15. Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the number of functionally mature dendritic cells in Flt3 ligand-treated mice. Multiple dendritic cell subpopulations identified. J Exp Med 1996;184:1953-62.
16. Ohteki T, Fukao T, Suzue K et al. Interferon-γ production by CD8α+ lymphoid dendritic cells in response to interleukin-12. J Exp Med 1999;189:1981-6.
17. Hayashi T, Takada H, Tanaka J et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002;104:14-20.
18. Homma S, Toda G, Gong J et al. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001;36:764-71.
19. Mule JJ, Shu S, Schwarz SL et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (Washington DC) 1984;225:1487-9.
20. Furumoto K, Arii S, Yamasaki S et al. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic anitumor immune responses. Int J Cancer 2000;87:665-72.
21. Anuraj H, Titus G. T cell and non-T cell compartments can independently determine resistance to Leshmania major. J Exp Med 1995;181:845-55.
22. Ulett GC, Ketheesan N, Hirst RG. Cytokine gene expression in innately susceprible BALB/c mice and relatively resistant C57BL/6 mice ding infection with virulent Burkholderia pseudomallei. Infect Immun 2000;68:2034-42.
23. Kronin V, Winkel K, Suss G et al. A subclass of dendritic cells regulates the response of naïve CD8 T cells by limiting their IL-2 production. J Immunol 1996;157:3819-27.
24. Leenen PJ, Radosevic K, Voerman JS et al. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity expression of macrophages markers, and subpopulatin turnover. J Immunol 1998;160:2166-73.
25. Pulendran B, Lingappa J, Kennedy MK et al. Developmental pathways of dendritic cells in vivo. Distinst function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-trated mice. J Immunol 1997;159:2222-31.
26. Vremec D, Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 1997;159:565-73.
27. Sato M, Iwakabe K, Ohta A et al. T. Functional heterogeneity among bone marrow-derived dendritic cells conditioned byTh1-and Th-2 biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes. Int Immunol 2000;12:335-42.
28. Tanaka Y, Koido S, Chen D et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC-1 transgenic mice. Clin Immunol 2001;101:192-200.
29. Cao X, Zhang W, Wang J et al. Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 1999;97:616-25.